Document:

Form of Common Stock Purchase Warrant

 Exhibit 4.3 
  

									
	             No.            
  
	  	 Common Stock Purchase Warrant
 Unless Extended By The Company This Warrant Expires
 At 5:00 P.M., New York Time on June 28, 2008
	  	 Warrants
  

					
	 	  		  	  
 ES Bancshares, Inc.
	  		  	  
 COMMON STOCK
 PURCHASE WARRANTS

			
	 	  	ORGANIZED UNDER THE LAWS OF THE STATE OF
 MARYLAND	  	 CUSIP
:                     

  
 THIS CERTIFIES THAT: 
 IS THE OWNER OF 
 Common Stock Purchase Warrants, each of
which entitles the owner thereof to purchase One fully paid and nonassesable share (subject to adjustment and hereinafter referred to) of the $5.00 par value Common Stock of ES Bancshares, Inc., upon surrender of this Warrant Certificate, duly
endorsed on the reverse hereof, together with payment in full of the purchase price in lawful money of the United States of America, at the principal office of the Company or its Warrant Agent. Warrants may be exercised until 5:00 P.M., New York
time on June 28, 2008 or such later date as may hereinafter be designated by the Company (the “Expiration Date”). The Purchase Price payable upon exercise of a Warrant (the “Purchase Price”) shall be at $12.50 and,
commencing on April 15, 2007, $10.00 per share. The Purchase Price shall be tendered with the properly completed and executed Form of Election on the reverse hereof, in cash or by bank teller’s check or personal check, all of which shall
be payable to the order of the Company and are accepted subject to collection. In the event that upon any exercise of Warrants evidenced hereby the number of Warrants exercised shall be less than the total number of Warrants evidenced hereby, there
shall be issued to the holder hereof, a new Warrant Certificate, in all respects similar to this Warrant Certificate, evidencing the number of Warrants not then exercised. This and similar Warrant Certificates when surrendered for partial exercise
by the registered holder hereof or by his/her duly authorized attorney or representative may be exchanged, without payment of any service charge, for a replacement certificate evidencing in the aggregate the number of Warrants then representing
unexercised. Prior to due presentment for registration of transfer of this Warrant Certificate, the Company may deem and treat the registered holder hereof as the absolute Owner of this Warrant Certificate (notwithstanding any position of ownership
or other writing hereof made by anyone other than the Company or its Warrant Agent) for the purpose of any exercise hereof and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary. In
the event that the transfer books for the Company’s Common Stock are closed, for any reason whatsoever, the Company and the Warrant Agent shall not be required to make delivery of certificates for Common Stock, until the date of the reopening
of said transfer books. No shares of Common Stock shall be issued pursuant to the exercise of Warrants unless such issuance and such exercise shall comply with all relevant provisions of law. 
 The Warrants evidenced hereby may not be exercised after the Expiration Date and to the extent not exercised by such time, all Warrants evidenced hereby
shall become null and void. During the exercise period, including any extended period, the Company agrees that it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the delivery of shares pursuant
to the exercise of this or any other such Warrants. This Warrant shall not entitle the holder hereof to any voting or other rights as a stockholder of the Company, or to any other rights whatsoever except the rights herein expressed and such as are
set 

 
forth, and no dividends shall be payable or accrue in respect of these Warrants or the interest represented hereby or the shares purchasable hereunder, until
or unless, and except to the extent that, these Warrants shall be exercised. 
 In case the Company shall at any time subdivide or combine its
outstanding shares of Common Stock into a greater or lesser number of shares by stock split, stock dividend, reverse stock split or otherwise, the number of shares issued upon exercise and the Purchase Price shall be proportionately adjusted to take
into account the effect of such subdivision or combination. In case the Company, or any successor, shall consolidate, merge or enter into a similar transaction with another entity or there is otherwise a reclassification, reorganization or change in
the Common Stock issuable upon exercise, the terms of this Warrant shall be appropriately adjusted and each share of Common Stock purchasable hereby shall be replaced for the purposes hereof by the securities or property issuable or distributable in
respect of each share of Common Stock of the Company or its successors upon such consolidation, merger, sale, reclassification, reorganization, change or similar transactions and adequate provision to that effect shall be made at the time thereof.
No fractional shares or scrip representing fractional shares shall be issued upon exercise hereof. 
 IN WITNESS WHEREOF, ES Bancshares, Inc.
has caused this Warrant Certificate to be signed manually, or in facsimile, by its Chief Executive Officer and the facsimile of its corporate seal to be imprinted hereon attested by the manual or facsimile signature of its Secretary or its Assistant
Secretary. 
  

					
	 DATED:
  
 ES BANCSHARES, INC.
	 		  	
			
	   	 	        [SEAL]        	  	   
	SECRETARY	 		  	CHIEF EXECUTIVE OFFICER

  
  
  
  

 ES Bancshares, Inc. 
 COMMON STOCK PURCHASE WARRANT 
 ELECTION TO PURCHASE 
 The undersigned hereby irrevocably elects to exercise the right of purchase represented by the within Warrant for, and to purchase thereunder,
             shares of Common Stock provided for therein and tenders herewith payment of the purchase price in full to the order of the Company and requests that certificates for
such shares shall be issued in the name of: 
  

			
	 PLEASE INSERT SOCIAL SECURITY OR
 OTHER IDENTIFYING NUMBER
	  	 
	 	
	  	  	 
	 	  	(PLEASE PRINT)

  

			
	and be delivered to 	  	  
		  	(NAME)

  

									
	at	  	  	  	  	  	  	  	  
		  	        (STREET ADDRESS)	  	(CITY)	  	        (STATE)            	  	(ZIP CODE)            

 and, if said number of shares shall not be all the shares purchasable thereunder, that a new Warrant for the
balance remaining of the shares purchasable under the within Warrant be registered in the name of, and delivered, to the undersigned at the address state below. 
  

			
	Name of Warrant holder: 	  	  
		  	(PLEASE PRINT)

  

			
	Address: 	  	  
		  	(STREET)

  

					
	 	  	 	  	 
	            (CITY)	  	                        (STATE)	  	(ZIP CODE)                

  

									
					
	Dated:	 	  	 		 		 	  
		 		 		 		 	Signature
		 		 		 		 	Note: The above signature must correspond with the name as written upon the face of this Warrant or with the name of the assignee appearing in the assignment form below in every particular
without alteration or enlargement or any change whatever.

 ASSIGNMENT 
 FOR VALUE RECEIVED
                                 hereby sell, assign and transfer unto 

 

			
	 PLEASE INSERT SOCIAL SECURITY OR
 OTHER IDENTIFYING NUMBER
	  	 
	 	
	  	  	 

  

	
	 
	PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS INCLUDING POSTAL ZIP CODE OF ASSIGNEE

  

	
	 

 the within Warrant, together with all right, title and interest therein, and do hereby irrevocable constitute and
appoint 
  

			
	  	 	attorney,

 to transfer said Warrant on the books of the within named Company, the full power of substitution in the premises.

  

									
					
	Dated:	 	  	 		 		 	  
		 		 		 		 	Signature
		 		 		 		 	Note: The above signature must correspond with the name as written upon the face of this Warrant in every particular without alteration or enlargement or any change whatever.

 PLEASE BE ADVISED THAT THE SECURITIES EVIDENCED BY THIS CERTIFICATE MAY BE HELD BY AN “AFFILIATE” FOR
PURPOSES OF RULE 144 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEREFORE, ANY PROSPECTIVE TRANSFEREE OF THE SECURITIES EVIDENCED BY THIS CERTIFICATE SHOULD OBTAIN AN OPINION OF COUNSEL PRIOR TO ACQUIRING THESE SECURITIES. 

THE SIGNATURE TO THE ASSIGNMENT OR THE SUBSCRIPTION FORM MUST CORRESPOND TO THE NAME AS WRITTEN UPON THE FACE OF THIS WARRANT CERTIFICATE IN EVERY PARTICULAR, WITHOUT
ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATSOEVER, AND MUST BE GUARANTEED BY A COMMERCIAL BANK OR TRUST COMPANY OR A MEMBER FIRM OF THE AMERICAN STOCK EXCHANGE, NEW YORK STOCK EXCHANGE, PACIFIC COAST STOCK EXCHANGE OR MIDWEST STOCK EXCHANGE.Note Purchase Agreement

 EXHIBIT 10.1 
 GEOPHARMA, INC. 
 SECURED CONVERTIBLE NOTE 
 PURCHASE AGREEMENT 
 April 5,
2007 

 SECURED CONVERTIBLE NOTE PURCHASE AGREEMENT 
 THIS SECURED CONVERTIBLE NOTE PURCHASE AGREEMENT (the “Agreement”) is made effective as of April 5, 2007, by and between GeoPharma,
Inc., a Florida corporation (the “Company”), and Whitebox Pharmaceutical Growth Fund, Ltd., a British Virgin Islands business company (the “Investor”), with respect to the following recitals. 
 RECITALS 
 A. The Company desires to
issue and sell and the Investor desires to purchase secured convertible promissory notes in substantially the form attached to this Agreement as Exhibit A (collectively, the “Notes”), which shall be convertible on the terms
stated therein into common stock, par value $.01 per share (the “Common Stock”), of the Company; and 
 B. As a further
inducement for Investor to purchase the Notes, the Company desires to provide a security interest in all assets of the Company as collateral to further secure the performance of the Company’s obligations under the Notes, as set forth in that
certain Security Agreement in the form attached hereto as Exhibit B (the “Security Agreement”). 
 AGREEMENT

 NOW, THEREFORE, in consideration of the respective representations, warranties, covenants and agreements contained herein, and
for other valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows: 
 ARTICLE
I 
 DEFINITIONS 
 Section 1.1 Specific Definitions. As used in this Agreement, the following terms shall have the meanings set forth or as referenced below: 
 “Action” shall have the meaning ascribed to such term in Section 4.10. 
 “Additional Notes” shall have the meaning ascribed to such term in Section 2.2. 
 “Affiliate” of a specified person (natural or juridical) means a person that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, that person, as such
terms are used in and construed under Rule 405 under the Securities Act. With respect to the Investor, any investment fund or managed account that is managed on a discretionary basis by the same investment manager as the Investor will be deemed to
be an Affiliate of the Investor. 
 “Agreement” means this Agreement and all Exhibits and Schedules hereto. 
 “Bank of America Loan Agreement” shall have the meaning ascribed to such term in Section 2.2. 
 “Code” shall have the meaning ascribed to such term in Section 4.38. 

 “Common Stock” means the Company’s common stock, par value $0.01 per share.

 “Conversion Price” means the conversion price in effect on any given date, which initially shall be equal to $4.36 but
which shall be subject to adjustment as described herein and in the Note. 
 “Common Stock Equivalents” means any securities
of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible
into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. 
 “Control”
shall mean ownership of more than 50% of the shares of stock entitled to vote for the election of directors in the case of a corporation, and more than 50% of the voting power in the case of a business entity other than a corporation. 
 “Conversion Shares” or “Shares” means the shares of Common Stock issued or issuable upon conversion of any of the
Convertible Notes. 
 “Convertible Note” or “Note” means each of the promissory notes, in the form attached
hereto as Exhibit A, to be issued by the Company to the Investor, including the Initial Note, the Additional Note and any Subsequent Note that may be issued to the Investor. 
 “Disclosure Schedules” means the Disclosure Schedules of the Company delivered concurrently herewith. 
 “Effective Date” means the date that the initial Registration Statement filed by the Company pursuant to the Registration Rights
Agreement is first declared effective by the Commission. 
 “Environmental Laws or Regulations” means any federal, state or
local statute, law, ordinance or regulation that relates to or deals with hazardous substances, human health or the environment, and all regulations promulgated by a regulatory body pursuant to any of the foregoing statutes, laws, regulations, or
ordinances. 
 “ERISA” shall have the meaning ascribed to such term in Section 4.38. 
 “Evaluation Date” shall have the meaning ascribed to such term in Section 4.18. 
 “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended to date. 
 “Exempt Issuance” means the issuance of (a) shares of Common Stock or options to employees, officers, consultants or directors of
the Company pursuant to the Company’s 1999 Employee Stock Option Plan, 1999 Non-Employee Director Stock Option Plan, Treasury Stock Repurchase Plan and Annual Performance Incentive Plan (provided that any such issuances shall not exceed 10% of
the Company’s outstanding shares and/or options, in the aggregate, in any twelve-month period), (b) securities upon the exercise or exchange of or conversion of any securities issued pursuant to the Purchase Agreement and/or other
securities exercisable or 

  

 2 

 
exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been
amended since the date of this Agreement to increase the number of such securities or to decrease the exercise, exchange or conversion price of such securities, and (c) securities issued pursuant to acquisitions or strategic transactions
approved by a majority of the disinterested directors of the Company, provided any such issuance shall only be to a person which is, itself or through its subsidiaries, an operating company in a business synergistic with or complementary to the
business of the Company and in which the Company receives benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity
whose primary business is investing in securities. 
 “FDA” shall have the meaning ascribed to such term in
Section 4.36. 
 “FDCA” shall have the meaning ascribed to such term in Section 4.36. 
 “Financial Statements” means the Company’s audited financial statements as of and for the year ended March 31, 2006 and any
unaudited quarterly financial statements of the Company for the quarters ended June 30, 2006, September 30, 2006 and December 31, 2006. 
 “GAAP” shall have the meaning ascribed to such term in Section 4.8. 
 “Guaranty” means that certain Guaranty, dated as of the date hereof, by the Company and certain of its Affiliates in favor of the Investor in the form attached hereto as Exhibit E. 
 “Hazardous Substances” means any and all substances (whether solid, liquid or gas) defined, listed, or otherwise classified as hazardous
wastes, hazardous substances, hazardous materials, extremely hazardous wastes, toxic substances, toxic pollutants, contaminants, pollutants or words of similar meaning or regulatory effect under any Environmental Laws or Regulations or that may have
a negative impact on human health or the environment or the presence of which on, in or under any property, is prohibited under Environmental Law, including petroleum and petroleum products, asbestos and asbestos-containing materials,
polychlorinated biphenyls, lead and radon, and compounds containing them (including gasoline, diesel fuel, oil and lead-based paint), and radioactive materials, flammables and explosives and compounds containing them. 
 “Indebtedness” shall have the meaning ascribed to such term in Section 4.27. 
 “Indemnifiable Losses” shall have the meaning ascribed to such term in Section 9.1. 
 “Initial Closing” shall have the meaning ascribed to such term in Section 3.1. 
 “Initial Closing Date” shall have the meaning ascribed to such term in Section 3.1. 
 “Initial Note” shall have the meaning ascribed to such term in Section 2.1. 
 “Initial Purchase Price” shall have the meaning ascribed to such term in Section 2.1. 
  

 3 

 “Intellectual Property” means (i) all proprietary rights, privileges and priorities
provided under U.S., state and foreign law relating to U.S. and foreign patents and patent applications, trademarks, service marks and registrations thereof and applications therefor, copyrights and copyright registrations and applications, mask
works and registrations thereof, know-how, and trade secrets; (ii) proprietary inventions, discoveries, ideas, technology, data, information, and processes; (iii) proprietary drawings, designs, licenses, computer programs and software, and
technical information including but not limited to proprietary information embodied in material specifications, processing instructions, equipment specifications, product specifications, confidential data, electronic files, research notebooks,
invention disclosures, research and development reports and the like related thereto; and (iv) all amendments, modifications, and improvements to any of the foregoing. 
 “Intellectual Property Rights” shall have the meaning ascribed to such term in Section 4.15. 
 “Knowledge” means actual knowledge of a fact or the knowledge which such person could reasonably be expected to have based on reasonable
inquiry. The knowledge of an entity shall include the knowledge of the individuals who are executive officers of such entity at the time in question. 
 “Legend Removal Date” shall have the meaning ascribed to such term in Section 6.13(c). 
 “Liens” means liens, mortgages, charges, security interests, claims, voting trusts, pledges, encumbrances, options, assessments, restrictions, or third-party or spousal interests of any nature. 
 “Material Adverse Effect” means any effect that may be materially adverse to (a) the business, operations, results of operations,
prospects, assets (including intangible assets), liabilities or condition (financial or otherwise) of the Company and its Affiliates, taken as a whole, or (b) the ability of the Company to perform its obligations under this Agreement or any of
the Transaction Documents or any other agreement or instrument to be entered into in connection with this Agreement. 
 “Material
Permits” shall have the meaning ascribed to such term in Section 4.13. 
 “Midsummer Purchase Agreement” shall
have the meaning ascribed to such term in Section 6.11(a). 
 “Mortgage” shall have the meaning ascribed to such term
in Section 6.19. 
 “Notice of Acceptance” shall have the meaning ascribed to such term in Section 6.11(b).

 “Offer” shall have the meaning ascribed to such term in Section 6.11(b). 
 “Offered Securities” shall have the meaning ascribed to such term in Section 6.11(b). 
 “Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited
liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. 
  

 4 

 “Plan” or “Plans” shall have the meaning ascribed to such term in
Section 4.38. 
 “Pledge Agreement” means the Pledge Agreement between the parties hereto in the form attached hereto
as Exhibit D. 
 “Proceeding” means an action, claim, suit, investigation or proceeding (including, without
limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened. 
 “Product
Liability” means any liability, claim or expense, including but not limited to attorneys’ fees and medical expenses, arising in whole or in part out of a breach of any express or implied product warranty by the Company, strict
liability in tort, negligent manufacture of product, negligent provision of services, product recall, or any other allegation of liability arising from the design, testing, manufacture, packaging, labeling (including instructions for use), or sale
of products. 
 “Purchased Securities” means the Convertible Notes and the Conversion Shares. 
 “Real Property” shall have the meaning ascribed to such term in Section 6.19. 
 “Refused Securities” shall have the meaning ascribed to such term in Section 6.11(b). 
 “Registration Rights Agreement” means the Registration Rights Agreement among the Company and the Investor in the form attached hereto
as Exhibit C. 
 “Registration Statement” means a registration statement meeting the requirements set forth in the
Registration Rights Agreement and covering the resale by the Investor of the Conversion Shares. 
 “Required Approvals”
shall have the meaning ascribed to such term in Section 4.5. 
 “Required Minimum” means, as of any date, the maximum
aggregate number of shares of Common Stock then issued or potentially issuable in the future pursuant to the Transaction Documents, including any Conversion Shares issuable upon exercise or conversion in full of all Notes, ignoring any conversion or
exercise limits set forth therein. 
 “Required Shareholder Approval Date” shall have the meaning ascribed to such term in
Section 6.16. 
 “Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule
may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 
 “Schedule of Exceptions” shall have the meaning ascribed to such term in Article 4. 
 “SEC” means the United States Securities and Exchange Commission or any other federal agency at the time administering the Securities Act. 
  

 5 

 “SEC Reports” shall have the meaning ascribed to such term in Section 4.8.

 “Securities Act” means the United States Securities Act of 1933, as amended, and all regulations promulgated thereunder.

 “Security Agreement” means the security agreement among the Company and the Investor in the form attached hereto as
Exhibit B, to be executed and delivered at the Closing. 
 “Shareholder Approval” means such approval as may be
required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor) from the shareholders of the Company with respect to the transactions contemplated by the Transaction Documents, including the issuance of all of the
Conversion Shares in excess of 19.99% of the issued and outstanding Common Stock on the Closing Date. 
 “Short Sales” means
all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock). 
 “Subsequent Notes” shall have the meaning ascribed to such term in Section 2.3. 
 “Subsequent Placement” shall have the meaning ascribed to such term in Section 6.11(a). 
 “Subsequent Placement Agreement” shall have the meaning ascribed to such term in Section 6.11(b). 
 “Subsequent Placement Documents” shall have the meaning ascribed to such term in Section 6.11(b). 
 “Subsidiary” means any subsidiary of the Company as set forth on Schedule 4.1 and shall, where applicable, include any subsidiary
of the Company formed or acquired after the date hereof. 
 “Trading Day” means a day on which the Nasdaq Stock Market (or
such other Trading Market on which the Company’s Common Stock is then traded) is open for trading. 
 “Trading Market”
means the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the American Stock Exchange, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New
York Stock Exchange or the OTC Bulletin Board. 
 “Transaction Documents” means the Notes, the Security Agreement, the
Pledge Agreement, the Registration Rights Agreement, the Guaranty, the Security Agreement, the Intercreditor Agreement and such other documents, instruments and agreements executed in connection with the consummation of the transactions contemplated
hereby. 
 “Variable Rate Transaction” shall have the meaning ascribed to such term in Section 6.12(b). 
  

 6 

 “VWAP” means, for any date, the price determined by the first of the following clauses
that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is
then listed or quoted for trading as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time); (b) if the OTC Bulletin Board is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on the OTC Bulletin Board; (c) if the Common Stock is not then quoted for trading on the OTC Bulletin Board and if prices for the Common Stock are then reported in the
“Pink Sheets” published by Pink Sheets, LLC (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported; or (d) in all other cases, the
fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company. 
 Section 1.2 Definitional Provisions. 
 (a) The words “hereof,”
“herein,” and “hereunder” and words of similar import, when used in this Agreement, shall refer to this Agreement as a whole and not to any particular provisions of this Agreement. 
 (b) The terms defined in the singular shall have a comparable meaning when used in the plural, and vice versa. Terms referring to a
masculine gender shall be deemed to refer to the feminine or neuter genders, as applicable. 
 (c) References to an
“Exhibit” or to a “Schedule” are, unless otherwise specified, to one of the Exhibits or Schedules attached to or referenced in this Agreement, and references to an “Article” or a “Section” are, unless
otherwise specified, to one of the Articles or Sections of this Agreement. 
 (d) The term “person” includes any
individual, partnership, joint venture, corporation, limited liability company, trust, entity, unincorporated organization or government or any department or agency thereof. 
 (e) The term “dollars” or “$” shall refer to the currency of the United States of America. 
 (f) All references to time shall refer to Minneapolis, Minnesota time. 
 ARTICLE II 
 PURCHASE AND SALE OF CONVERTIBLE NOTES 
 Section 2.1 Purchase and Sale of Initial Notes. Subject to the terms and conditions of this Agreement, the Investor agrees to purchase at the
Closing, and the Company agrees to sell and issue to the Investor at the Closing, a Note, in substantially the form attached hereto as Exhibit A, in the original principal amount of $10,000,000 (the “Initial Note”), at a
purchase price equal to 100% of the principal amount thereof (the “Initial Purchase Price”). The Initial Note will be secured pursuant to the Security Agreement. 
  

 7 

 Section 2.2 Purchase and Sale of Additional Notes. Between the Closing Date and
September 30, 2007, the Investor will have the option, in its sole discretion, to purchase an additional $5,000,000 of Notes (the “Additional Notes”) on the same terms and conditions specified in this Agreement with respect to
the Initial Note; provided, however, that the foregoing issuance of Subsequent Notes may be extended until December 31, 2007 if the issuance of such Additional Notes would cause the Company to violate the debt-to-equity ratios set
forth in that certain loan and credit facility with Bank of America entered into on February 27, 2007 (as the same may be amended, modified or supplemented from time to time, the “Bank of America Loan Agreement”). The
Additional Notes will be issued to the Investor in the original principal amount of $5,000,000, at a purchase price equal to 100% of the principal amount thereof. The Additional Notes will be secured pursuant to the Security Agreement. 

Section 2.3 Purchase and Sale of Subsequent Notes. Subject to the terms and conditions of this Agreement, on and after September 30,
2007, if (a) the Company’s generic pharmaceutical drug revenues exceed $3,000,000 in any quarterly period (as reflected in the Company’s Quarterly Report on Form 10-Q or Annual Report on Form 10-K, as applicable) and (b) the
Company has received Shareholder Approval, Investor agrees to invest an additional $5,000,000 in Notes (the “Subsequent Notes”) on the same terms and conditions specified in this Agreement with respect to the Initial Note and the
Additional Notes; provided, however, that the foregoing issuance of Subsequent Notes may be extended until December 31, 2007 if the issuance of such Subsequent Notes would cause the Company to violate the debt-to-equity ratios set
forth in the Bank of America Loan Agreement. The Subsequent Notes will be issued to the Investor in the original principal amount of $5,000,000, at a purchase price equal to 100% of the principal amount thereof. The Subsequent Notes will also be
secured pursuant to the Security Agreement. 
 Section 2.4 Note Conversion. The Investor may, at its option, purchase shares of
the Company’s Common Stock by converting amounts outstanding under the Initial Note or, if applicable, the Additional Note and the Subsequent Note, at the applicable Conversion Price as provided therein (in each case, a “Note Conversion
Closing”). At each Note Conversion Closing, the Company shall issue certificates representing any shares purchased under this Section 2.4 in a form acceptable to the Investor and Investor’s counsel, and the Investor shall pay the
Conversion Price of $4.36 per share (subject to adjustment as provided therein) for such shares by surrendering the applicable Note(s) to the Company. 
 Section 2.5 Use of Proceeds. The Company shall use the cash proceeds of the sale of the Initial Notes (a) for the Company’s working capital needs, (b) to pay any legal fees and expenses
incurred in connection with the drafting, negotiation, due diligence and execution of this Agreement and the other Transaction Documents (including those documents delivered in connection with the issuance of the Note and the Conversion Shares to
the Investor on the Closing Date) and (c) to pay any commissions owed to the placement agent as a result of the issuance of the Notes. 
  

 8 

 ARTICLE III 
 THE CLOSING 
 Section 3.1 Closing. 
 (a) Initial Closing. The purchase and sale of the Initial Notes shall take place at the offices of the Company, at 10:00 a.m., on
April 5, 2007, or such other time as may be designated by the Company in writing (the “Initial Closing”). At the Initial Closing, the Company shall deliver to the Investor the Initial Note that the Investor is purchasing
against delivery to the Company by the Investor of a check or wire transfer in the amount of $10,000,000.00 payable to the Company’s order (or by wire of funds in such amount to the Company’s designated bank account). 
 (b) Subsequent Closings. The purchase and sale of the Additional Notes shall occur within five (5) business days of the
Investor’s notice to the Company of the exercise of its option to purchase the Additional Notes. The purchase and sale of the Subsequent Notes shall occur within five (5) business days of the satisfaction of the conditions set forth in
Section 2.3 of this Agreement. 
 Section 3.2 Closing Deliveries. 
 (a) Company Deliveries. On the Initial Closing Date, the Company shall deliver or cause to be delivered to the Investor the
following: 
 (i) this Agreement duly executed by the Company; 
 (ii) a Note registered in the name of the Investor in the principal amount of $10,000,000; 
 (iii) the Security Agreement, in substantially the form attached hereto as Exhibit B (the “Security Agreement”),
duly executed by the Company; 
 (iv) the Registration Rights Agreement, in substantially the form attached hereto as
Exhibit C (the “Registration Rights Agreement”), duly executed by the Company; 
 (v) the Pledge
Agreement, in substantially the form attached hereto as Exhibit D (the “Pledge Agreement”), duly executed by the Company and certain of its Affiliates; 
 (vi) the Guaranty, in substantially the form attached hereto as Exhibit E (the “Guaranty”), executed by the
Company and certain of its Affiliates in favor of the Investor; 
 (vii) the Intercreditor Agreement, in substantially the
form attached hereto as Exhibit F, executed by Bank of America, N.A. (the “Intercreditor Agreement”); and 
  

 9 

 (viii) the written voting agreements, in the form attached hereto as Exhibit G
(the “Voting Agreements”), on the date hereof, of certain shareholders of the Company listed on Exhibit H attached hereto, whereby such shareholders have agreed to vote all Common Stock over which such shareholders have
voting control as of the record date for the 2007 Annual Meeting of Shareholders of the Company in favor of Shareholder Approval, amounting to, in the aggregate, in excess of 25% of the issued and outstanding shares of the Company’s Common
Stock. 
 (b) Investor Deliveries. On the Initial Closing Date, the Investor shall deliver or cause to be delivered to
the Company the following: 
 (i) this Agreement duly executed by the Investor; 
 (ii) the Registration Rights Agreement duly executed by the Investor; 
 (iii) the Intercreditor Agreement, in substantially the form attached hereto as Exhibit F, duly executed by the Investor; and

 (iv) the payment of the Initial Purchase Price by the Investor, in the manner specified in Section 3.1 above.

 ARTICLE IV 
 REPRESENTATIONS AND WARRANTIES OF THE COMPANY 
 Attached hereto as Schedule A is the Schedule of Exceptions containing
sections numbered to correspond to the sections of this Article 4 (the “Schedule of Exceptions”). Except as specifically set forth in the corresponding section of such Schedule of Exceptions (or in any other section of the Schedule
of Exceptions so long as the applicability of such disclosure to the particular representation and warranty which such disclosure is intended to modify is reasonably apparent), the Company and its Affiliates hereby represents and warrants to the
Investor as follows as of the date hereof and as of the Closing Date: 
 Section 4.1 Subsidiaries. All of the direct and indirect
subsidiaries (the “Subsidiaries”) of the Company are set forth on Schedule 4.1. The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and
all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries,
then all other references to the Subsidiaries or any of them in the Transaction Documents shall be disregarded. 
 Section 4.2
Organization and Qualification. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization (as
applicable), with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation or default of any of the provisions of its
respective certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified 

  

 10 

 
to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or
property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in a Material Adverse Effect, and no Proceeding has been
instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification. 
 Section 4.3 Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by each of the Transaction Documents and
otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of each of the Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized
by all necessary action on the part of the Company and no further action is required by the Company, its board of directors or its shareholders in connection therewith other than in connection with the Required Approvals (as defined in
Section 4.5 below). Each Transaction Document has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the
Company enforceable against the Company in accordance with its terms except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting
enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions
may be limited by applicable law. 
 Section 4.4 No Conflicts. The execution, delivery and performance of the Transaction
Documents by the Company, the issuance and sale of the Purchased Securities and the consummation by the Company of the other transactions contemplated hereby and thereby do not and will not (i) conflict with or violate any provision of the
Company’s or any Subsidiary’s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would
become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of
time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the
Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals (as defined in Section 4.5 below), conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other
restriction of any court or governmental authority to which the Company or any Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or
affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect. 
 Section 4.5 Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or
other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction 

  

 11 

 
Documents, other than (i) filings required pursuant to Section 6.14 of this Agreement, (ii) the filing with the Commission of the Registration
Statement, (iii) application(s) to each applicable Trading Market for the listing of the Securities for trading thereon in the time and manner required thereby, and (iv) the filing of Form D with the Commission and such filings as are
required to be made under applicable state securities laws (collectively, the “Required Approvals”). 
 Section 4.6
Issuance of the Securities. The Purchased Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of
all Liens imposed by the Company other than restrictions on transfer provided for in the Transaction Documents. The Conversion Shares, when issued in accordance with the terms of the Transaction Documents, will be validly issued, fully paid and
nonassessable, free and clear of all Liens imposed by the Company other than restrictions on transfer provided for in the Transaction Documents. The Company has reserved from its duly authorized capital stock the maximum number of shares of Common
Stock issuable pursuant to this Agreement and the other Transaction Documents. 
 Section 4.7 Capitalization. The capitalization
of the Company is as set forth on the Schedule of Exceptions, which Schedule of Exceptions shall also include the number of shares of Common Stock owned of record, and, to the knowledge of the Company, beneficially, by Affiliates of the Company as
of the date hereof. The Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock options under the Company’s stock option plans, the
issuance of shares of Common Stock to employees pursuant to the Company’s employee stock purchase plans and pursuant to the conversion or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report
under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as set forth on the Schedule of
Exceptions or as a result of the purchase and sale of the Purchased Securities, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or
obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary
is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents. The issuance and sale of the Purchased Securities will not obligate the Company to issue shares of Common Stock or other securities to any Person (other
than the Investor) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities. All of the outstanding shares of capital stock of the Company are validly
issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase
securities. No further approval or authorization of any shareholder, the Board of Directors of the Company or others is required for the issuance and sale of the Purchased Securities. There are no stockholder agreements, voting agreements or other
similar agreements with respect to the Company’s capital stock to which the Company is a party (other than those contemplated in connection with the Transaction Documents) or, to the knowledge of the Company, between or among any of the
Company’s shareholders. 
  

 12 

 Section 4.8 SEC Reports; Financial Statements. The Company has filed all reports, schedules,
forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period
as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the “SEC
Reports”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material
respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable
accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles
applied on a consistent basis during the periods involved (“GAAP”), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes
required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject,
in the case of unaudited statements, to normal, immaterial, year-end audit adjustments. 
 Section 4.9 Material Changes; Undisclosed
Events, Liabilities or Developments. Since the date of the latest audited financial statements included within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof, (i) there has been
no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and
accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP or disclosed in filings made with the
Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its shareholders or purchased, redeemed or made any agreements to
purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans. The Company does not have pending before
the Commission any request for confidential treatment of information. Except for the issuance of the Purchased Securities contemplated by this Agreement or as set forth on Schedule 4.9, no event, liability or development has occurred or
exists with respect to the Company or its Subsidiaries or their respective business, properties, operations or financial condition, that would be required to be disclosed by the Company under applicable securities laws at the time this
representation is made or deemed made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made. 
 Section 4.10 Litigation. There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the 

  

 13 

 
Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory
authority (federal, state, county, local or foreign) (collectively, an “Action”) which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Purchased Securities
or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action
which has resulted in a final judgment involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or
contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration
statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act. 
 Section 4.11 Labor Relations.
No material labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company which could reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its
Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the
Company and its Subsidiaries believe that their relationships with their employees are good. No executive officer, to the knowledge of the Company, is, or is now expected to be, in violation of any material term of any employment contract,
confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer
does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating
to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 Section 4.12 Compliance. Neither the Company nor any Subsidiary (i) is in default under or in violation of (and no event
has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that
it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in
violation of any order of any court, arbitrator or governmental body, or (iii) is or has been in violation of any statute, rule or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws
applicable to its business and all such laws that affect the environment, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect. 
 Section 4.13 Regulatory Permits. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the
appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC 

  

 14 

 
Reports, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (“Material
Permits”), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit. 
 Section 4.14 Title to Assets. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable title in all personal property owned
by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for Liens that do not materially affect the value of such property and do not materially interfere with the use made and
proposed to be made of such property by the Company and the Subsidiaries and Liens for the payment of federal, state or other taxes, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under
lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance in all material respects. 
 Section 4.15 Patents and Trademarks. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications,
trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary or material for use in connection with their respective businesses as
described in the SEC Reports and which the failure to so have could have a Material Adverse Effect (collectively, the “Intellectual Property Rights”). Neither the Company nor any Subsidiary has received a notice (written or
otherwise) that any of the Intellectual Property Rights used by the Company or any Subsidiary violates or infringes upon the rights of any Person. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no
existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties,
except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 
 Section 4.16 Insurance. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which
the Company and the Subsidiaries are engaged, including, but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company nor any Subsidiary has any reason to believe that it will
not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost. 
 Section 4.17 Transactions With Affiliates and Employees. Except as set forth in the SEC Reports, none of the officers or directors of the
Company and, to the knowledge of the Company, none of the employees of the Company is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of
the 

  

 15 

 
Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner, in each
case in excess of $100,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option
agreements under any stock option plan of the Company. 
 Section 4.18 Sarbanes-Oxley; Internal Accounting Controls. The Company
is in material compliance with all provisions of the Sarbanes-Oxley Act of 2002 which are applicable to it as of the Closing Date. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable
assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to
maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at
reasonable intervals and appropriate action is taken with respect to any differences. The Company has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and designed such
disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the
Commission’s rules and forms. The Company’s certifying officers have evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by the Company’s most recently filed
periodic report under the Exchange Act (such date, the “Evaluation Date”). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of
the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the Company’s internal control over financial reporting (as such term is defined in the
Exchange Act) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting. 
 Section 4.19 Certain Fees. Except for fees payable to Rodman & Renshaw, LLC, no brokerage or finder’s fees or commissions are or will be payable by the Company to any broker, financial
advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Investor shall have no obligation with respect to any fees or with respect to any
claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents. 
 Section 4.20 Private Placement. Assuming the accuracy of the Investor representations and warranties set forth in Article 5, no registration
under the Securities Act is required for the offer and sale of the Purchased Securities by the Company to the Investor as contemplated hereby. The issuance and sale of the Purchased Securities hereunder does not contravene the rules and regulations
of the Trading Market. 
 Section 4.21 Investment Company. The Company is not, and is not an Affiliate of, and immediately after
receipt of payment for the Securities, will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not
become subject to the Investment Company Act of 1940, as amended. 
  

 16 

 Section 4.22 Registration Rights. Other than each of the Investor, no Person has any right to
cause the Company to effect the registration under the Securities Act of any securities of the Company, other than registration statements which have already been filed and declared effective. 
 Section 4.23 Listing and Maintenance Requirements. The Company’s Common Stock is registered pursuant to Section 12(b) or 12(g) of
the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification that
the Commission is contemplating terminating such registration. The Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the
Company is not in compliance with the listing or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and
maintenance requirements. 
 Section 4.24 Application of Takeover Protections. The Company and its board of directors have taken
all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Company’s
articles of incorporation (or similar charter documents) or the laws of its state of incorporation that is or could become applicable to the Investor as a result of the Investor and the Company fulfilling their obligations or exercising their rights
under the Transaction Documents, including without limitation as a result of the Company’s issuance of the Purchased Securities and the Investor’s ownership of the Purchased Securities. 
 Section 4.25 Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided the Investor or its agents or counsel with any information that it believes constitutes or might constitute material, non-public information. The
Company understands and confirms that the Investor will rely on the foregoing representation in effecting transactions in securities of the Company. All disclosure furnished by or on behalf of the Company to the Investor regarding the Company, its
business and the transactions contemplated hereby, including the SEC Reports and the Disclosure Schedules to this Agreement, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The press releases and the SEC Reports filed or disseminated by the Company during the twelve months preceding the date
of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which
they were made and when made, not misleading. The Company acknowledges and agrees that the Investor is not making and has not made any representations or warranties with respect to the transactions contemplated hereby other than those specifically
set forth in Article 5 below. 
  

 17 

 Section 4.26 No Integrated Offering. Assuming the accuracy of the Investor’s
representations and warranties set forth in Article 5, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy
any security, under circumstances that would cause this offering of the Purchased Securities to be integrated with prior offerings by the Company for purposes of (i) the Securities Act which would require the registration of any such securities
under the Securities Act, or (ii) any applicable shareholder approval provisions of any Trading Market on which any of the securities of the Company are listed or designated. 
 Section 4.27 Solvency. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the
receipt by the Company of the proceeds from the sale of the Purchased Securities hereunder, (i) the fair saleable value of the Company’s assets exceeds the amount that will be required to be paid on or in respect of the Company’s
existing debts and other liabilities (including known contingent liabilities) as they mature; (ii) the Company’s assets do not constitute unreasonably small capital to carry on its business as now conducted and as proposed to be conducted
including its capital needs taking into account the particular capital requirements of the business conducted by the Company, and projected capital requirements and capital availability thereof; and (iii) the current cash flow of the Company,
together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts
are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of
any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. Schedule 4.27 sets forth as of the date
thereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, “Indebtedness” means (a) any
liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (b) all guaranties, endorsements and other contingent obligations in respect of Indebtedness of
others, whether or not the same are or should be reflected in the Company’s balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary
course of business; and (c) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.

 Section 4.28 Tax Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected
to result in a Material Adverse Effect, the Company and each Subsidiary has filed all necessary federal, state and foreign income and franchise tax returns and has paid or accrued all taxes shown as due thereon, and the Company has no knowledge of a
tax deficiency which has been asserted or threatened against the Company or any Subsidiary. 
 Section 4.29 No General
Solicitation. Neither the Company nor any person acting on behalf of the Company has offered or sold any of the Purchased Securities by any form of general solicitation or general advertising. The Company has offered the Securities for sale only
to the Investor and certain other “accredited investors” within the meaning of Rule 501 under the Securities Act. 
  

 18 

 Section 4.30 Foreign Corrupt Practices. Neither the Company, nor to the knowledge of the
Company, any agent or other person acting on behalf of the Company, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity,
(ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company
(or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended. 
 Section 4.31 Accountants. The Company’s accounting firm is set forth on Schedule 4.31 of the Disclosure Schedule. To the
knowledge and belief of the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion with respect to the financial statements to be included in the
Company’s Annual Report on Form 10-KSB for the year ending March 31, 2007. 
 Section 4.32 No Disagreements with
Accountants and Lawyers. There are no disagreements of any kind presently existing, or reasonably anticipated by the Company to arise, between the Company and the accountants and lawyers formerly or presently employed by the Company which could
affect the Company’s ability to perform any of its obligations under any of the Transaction Documents, and the Company is current with respect to any fees owed to its accountants and lawyers. 
 Section 4.33 Acknowledgment Regarding Investor’s Purchase of Securities. The Company acknowledges and agrees that the Investor is acting
solely in the capacity of an arm’s-length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company further acknowledges that the Investor is not acting as a financial advisor or fiduciary of the
Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by the Investor or any of its representatives or agents in connection with the Transaction Documents and
the transactions contemplated thereby is merely incidental to the Investor’s purchase of the Purchased Securities. The Company further represents to the Investor that the Company’s decision to enter into this Agreement and the other
Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives. 
 Section 4.34 Acknowledgement Regarding Investor’s Trading Activity. Anything in this Agreement or elsewhere herein to the contrary notwithstanding, it is understood and acknowledged by the Company
(i) that the Investor has not been asked by the Company to agree, nor has the Investor agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or “derivative” securities based on securities issued
by the Company or to hold the Purchased Securities for any specified term; (ii) that past or future open market or other transactions by the Investor, including Short Sales, and specifically including, without limitation, Short Sales or
“derivative” transactions, before or after the closing of this or future private 

  

 19 

 
placement transactions, may negatively impact the market price of the Company’s publicly traded securities; (iii) that the Investor, and
counter-parties in “derivative” transactions to which the Investor is a party, directly or indirectly, presently may have a “short” position in the Common Stock, and (iv) that the Investor shall not be deemed to have any
affiliation with or control over any arm’s-length counter-party in any “derivative” transaction. The Company further understands and acknowledges that (a) the Investor may engage in hedging activities at various times during the
period that the Purchased Securities are outstanding, including, without limitation, during the periods that the value of the Conversion Shares deliverable with respect to the Notes are being determined and (b) such hedging activities (if any)
could reduce the value of the existing shareholders’ equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not
constitute a breach of any of the Transaction Documents. 
 Section 4.35 Regulation M Compliance. The Company has not, and to its
knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of
the Purchased Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Purchased Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to
purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company’s placement agent in connection with the placement of the Purchased Securities. 
 Section 4.36 FDA. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the
Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries, such product is
being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use,
premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure
to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company’s knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge,
complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which
(i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any product, (ii) withdraws
its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any product, (iii) imposes a clinical hold on any clinical investigation by the
Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its
Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties,
business and operations of the Company have been and are being 

  

 20 

 
conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the
FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any
product being developed or proposed to be developed by the Company. 
 Section 4.37 Form S-3 Eligibility. The Company is eligible
to register the resale of the Securities for resale by the Investor on Form S-3 promulgated under the Securities Act. 
 Section 4.38
Employee Benefit Plans. 
 (a) Except as set forth in the Schedule of Exceptions, (i) the Company does not
maintain or contribute to or have any obligation to contribute to, or have any direct or indirect liability, whether contingent or otherwise, with respect to any plan, program, agreement, arrangement or commitment which is an employment, consulting
or deferred compensation agreement, or an executive compensation, incentive bonus or other bonus, employee pension, profit-sharing, savings, retirement, stock option, stock purchase, severance pay, life, health, disability or accident insurance
plan, or vacation, or other employee benefit plan, program, arrangement, agreement or commitment, whether or not subject to ERISA (as defined below) (including any funding mechanism now in effect or required in the future as a result of the
transaction contemplated by this Agreement or otherwise), whether oral or written (individually a “Plan,” and collectively, the “Plans”); and (ii) neither the Company nor any person who would be considered a
single employer with the Company pursuant to Section 414(b), (c), (m) or (o) of the Code (as defined below) maintains or contributes to, or has had during the preceding six years maintained or contributed to, or has had during such
period the obligation to maintain or contribute, or may have any liability with respect to, any Plan subject to Title IV of ERISA or Section 412 of the Code or any “multiple employer plan” within the meaning of the Code or ERISA. No
Plan is (i) a nonqualified deferred compensation retirement plan, contract or arrangement; (ii) a qualified defined contribution plan (as defined in Section 3(34) of the Employee Retirement Income Security Act of 1974, as amended
(“ERISA”), or Section 414(i) of the Internal Revenue Code of 1986, as amended (the “Code”)); (iii) a qualified defined benefit plan (as defined in Section 3(35) of ERISA or Section 414(j) of the
Code); or (iv) an employee welfare benefit plan (as defined in Section 3(1) of ERISA). 
 (b) To the extent required
(either as a matter of law or to obtain the intended tax treatment and tax benefits), all employee benefit plans (as defined in Section 3(3) of ERISA), which the Company maintains or to which it contributes, comply in all material respects with
the requirements of ERISA and the Code. With respect to the Plans, (i) all required contributions which are due have been made and a proper accrual has been made for all contributions due in the current fiscal year; (ii) there have been no
prohibited transactions (as defined in Section 406 of ERISA or Section 4975 of the Code) and (iii) no event has occurred in connection with which the Company or any Plan could be subject to any material liability under ERISA, the Code
or otherwise. 
  

 21 

 (c) The Company does not contribute (and has not ever contributed or had any obligation
to contribute) to any multi-employer plan, as defined in Section 3(37) of ERISA. The Company has no actual or potential liabilities under Section 4201 of ERISA for any complete or partial withdrawal from a multi-employer plan. The Company
has no actual or potential liability for death or medical benefits after separation from employment, other than (i) death benefits under the employee benefit plans or programs (whether or not subject to ERISA) set forth in the Schedule of
Exceptions and (ii) health care continuation benefits described in Section 4980B of the Code. 
 (d) To the
Company’s knowledge, neither the Company nor any of its directors, officers, employees or other “fiduciaries,” as such term is defined in Section 3(21) of ERISA, has committed any breach of fiduciary responsibility imposed by
ERISA or any other applicable law with respect to the Plans which would subject the Company or any of its directors, officers or employees to any liability under ERISA or any applicable law. 
 (e) The Company has not incurred any liability for any tax or civil penalty or any disqualification of any employee benefit plan (as
defined in Section 3(3) of ERISA) imposed by Sections 4980B and 4975 of the Code and Part 6 of Title I and Section 502(i) of ERISA. 
 Section 4.39 Product Liability Claims. All products manufactured, distributed or sold by or on behalf of the Company were merchantable, free from defects in design, specifications, processing, manufacture, material or
workmanship, and suitable for the purpose for which they were intended. The Company has not incurred any uninsured or insured Product Liability, or received a claim based upon alleged Product Liability, and no basis for any such claim exists. The
Company has no liability or obligation with respect to any Product Liability, whether or not heretofore asserted, or product recall. The Company has maintained complete and accurate complaint histories regarding the Company’s products.

 Section 4.40 Outstanding Borrowing. The Schedule of Exceptions sets forth the amount of all indebtedness of the Company as of
the date hereof, the liens that relate to such indebtedness and that encumber the Company’s assets and the name of each lender thereof. No holder of indebtedness of the Company is entitled to any voting rights in any matters voted upon by the
holders of the Common Stock. 
 ARTICLE V 
 REPRESENTATIONS AND WARRANTIES OF THE INVESTOR 
 The Investor represents and warrants to the Company
for itself as follows: 
 Section 5.1 Authorization. The Investor has full power and authority to enter into and perform under
this Agreement in accordance with its terms. This Agreement has been duly authorized by all necessary action on the part of the Investor, has been duly executed and delivered by each the Investor, and is the valid and binding agreement of each the
Investor and is enforceable against each the Investor in accordance with its terms, except as enforceability may be limited by bankruptcy, insolvency, moratorium, reorganization or other similar laws affecting the enforcement of creditors’
rights generally and to judicial limitations on the remedy of specific enforcement and other equitable remedies. 
  

 22 

 Section 5.2 Purchase Entirely for Own Account. This Agreement is made with the Investor in
reliance upon the Investor’s representation to the Company, which by the Investor’s execution of this Agreement the Investor hereby confirms, that the Purchased Securities will be acquired for investment for the Investor’s own
account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that the Investor has no present intention of selling, granting any participation in, or otherwise distributing the same. By executing
this Agreement, the Investor further represents that the Investor does not have any contract, undertaking, agreement or arrangement with any third-party to sell, transfer or grant participations to such third-party or to any third-person, with
respect to any of the Purchased Securities. 
 Section 5.3 Reliance Upon Investor’s Representations; Restrictions on Resale.
The Investor understands that none of the Notes or Conversion Shares have been registered under the Securities Act or any state securities laws by reason of their contemplated issuance in transactions exempt from the registration requirements of the
Securities Act pursuant to Section 4(2) thereof or Rule 505 or 506 promulgated under the Securities Act and applicable state securities laws, and that the reliance of the Company and others upon these exemptions is predicated in part upon this
representation by the Investor. The Investor further understands that the Notes and the Conversion Shares may not be transferred or resold without (i) registration under the Securities Act and any applicable state securities laws, or
(ii) an exemption from the requirements of the Securities Act and applicable state securities laws. The Investor also understands that any Conversion Shares will be issued without prior registration thereof under the Securities Act or
applicable state securities laws in reliance upon Section 4(2) of the Securities Act and transactional exemptions from registration under applicable state securities laws based upon appropriate representations of the Investor. As such, the
Conversion Shares will be subject to transfer restrictions similar to restrictions applicable to the Convertible Notes. The Investor understands (i) that an exemption from such registration is not presently available pursuant to Rule 144
promulgated under the Securities Act by the SEC and (ii) that in any event the Investor may not sell any securities acquired hereunder pursuant to Rule 144 prior to the expiration of a one-year period (or such shorter period as the Commission
may hereafter adopt) after the Investor has acquired such securities. The Investor understands that any sales pursuant to Rule 144 can be made only in full compliance with the provisions of Rule 144. 
 Section 5.4 Receipt of Information. The Investor represents that the Company has provided the Investor at a reasonable time prior to the
execution of this Agreement sufficient opportunity to ask questions and receive answers from the Company’s management concerning the Company’s business, management and financial affairs and the terms and conditions of the offering of the
Purchased Securities and the Conversion Shares and to obtain any additional information (which the Company possesses or can acquire without unreasonable effort or expense) as may be necessary to verify the accuracy of information furnished to the
Investor. The Investor has reviewed the representations concerning the Company contained in this Agreement. The foregoing, however, does not limit or modify the representations and warranties of the Company in this Agreement or the right of the
Investor to rely thereon. 
  

 23 

 Section 5.5 Investment Experience. The Investor represents that it is experienced in
evaluating and investing in securities of companies in the development stage and acknowledges that it is able to fend for itself, can bear the economic risk of its investment, and has such knowledge and experience in financial or business matters
that it is capable of evaluating the merits and risks of the investment in the Notes and the Conversion Shares. If other than an individual, Investor also represents it has not been organized for the purpose of acquiring the Notes and Conversion
Shares. 
 Section 5.6 Accredited Investor. The Investor is an “accredited investor” within the meaning of SEC Rule 501
of Regulation D promulgated under the Act, as presently in effect. 
 Section 5.7 Legends. To the extent applicable, each
certificate or other document evidencing any of the Purchased Securities shall be endorsed with the legends set forth below, and the Investor covenants that, except to the extent such restrictions are waived by the Company, the Investor shall not
transfer the shares represented by any such certificate without complying with the restrictions on transfer described in the legends endorsed on such certificate: 
 “THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED ABSENT AN EFFECTIVE
REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH RULE 144 PROMULGATED UNDER SUCH ACT, OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.”

 The Company shall make a notation regarding the restrictions on transfer of the Conversion Shares or other Purchased Securities in its books and the
Conversion Shares and other Purchased Securities shall be transferred on the books of the Company only if transferred or sold pursuant to an effective registration statement under the Securities Act covering the securities to be transferred or an
opinion of counsel reasonably satisfactory to the Company that such registration is not required; provided, however, that (i) the Company will not require opinions of counsel for transactions made pursuant to Rule 144 except in
unusual circumstances and (ii) the Company will not require opinions of counsel for transfers to affiliated entities managed by the same manager or managing partner or management company, or managed by an entity controlling, controlled by or
under common control with such manager, managing partner or management company so long as the transferor certifies in writing to the Company that the transferor is not receiving any consideration in connection with the transfer and so long as the
transferee will be subject to the terms of these restrictions to the same extent as if such transferee were an original Investor hereunder. 
  

 24 

 ARTICLE VI 
 COVENANTS 
 The Company covenants that for so long as any Notes remain outstanding: 
 Section 6.1 Financial Statements, Reports, Etc. The Company shall furnish to the Investor: 
 (a) within ninety (90) days (or such shorter period of time as shall be required by the SEC in connection with the filing of the
Company’s quarterly reports with the SEC under the Exchange Act) after the end of each fiscal year of the Company ending on or after December 31, 2006, a balance sheet of the Company as of the end of such fiscal year and the related
statements of income, stockholders’ equity and cash flows for the fiscal year then ended, prepared in accordance with GAAP and certified by a firm of independent public accountants; 
 (b) within forty-five (45) days (or such shorter period of time as shall be required by the SEC in connection with the filing of the
Company’s annual reports with the SEC under the Exchange Act) after the end of each fiscal quarter in each fiscal year (other than the last fiscal quarter in each fiscal year) an unaudited balance sheet of the Company and the related unaudited
statements of income, stockholders’ equity and cash flows, and certified by the Chief Financial Officer of the Company, such balance sheet to be as of the end of such fiscal quarter and such statements of income, stockholders’ equity and
cash flows to be for such fiscal quarter and for the period from the beginning of the fiscal year to the end of such fiscal quarter, in each case with comparative statements for the corresponding period in the prior fiscal year; 
 (c) promptly after receipt by the Company of notice thereof, notice of all actions, suits, claims, proceedings, investigations and
inquiries that could have a Material Adverse Effect; and 
 (d) promptly, from time to time, such other information regarding
the business, financial condition, operations, property or affairs of the Company and its subsidiaries as the Investor may reasonably request. 
 Section 6.2 Inspection, Consultation and Advice. The Company shall permit the Investor and such persons as the Investor may designate, at the Investor’s expense, upon reasonable notice and at such times as the Investor may
reasonably request to visit and inspect any of the properties of the Company, examine its books and records (including without limitation product complaint histories and related information) and take copies and extracts therefrom, discuss the
affairs (including, without limitation, operations and relations with suppliers), finances and accounts of the Company with its officers, employees and public accountants (and the Company hereby authorizes said accountants to discuss with the
Investor and any such designees such affairs, finances and accounts), and consult with the management of the Company as to such affairs, finances and accounts of the Company and its subsidiaries, all at reasonable times and upon reasonable notice.

  

 25 

 Section 6.3 Transactions with Affiliates. Except for transactions contemplated by this
Agreement or as otherwise approved by a majority of the disinterested directors on the Company’s Board of Directors, the Company shall not enter into any transaction with any director, officer, employee or holder of more than 5% of the
outstanding capital stock of the Company, any member of the family of any such person, or any corporation, partnership, trust or other entity in which any such person, or member of the family of any such person, is a director, officer, trustee,
partner or holder of more than 5% of the outstanding capital stock thereof, except for transactions on customary terms related to such person’s employment or service as a director of the Company. Except as specifically disclosed on Schedule 6.3
attached hereto, the Company shall not use any proceeds of Purchased Securities to make distributions or loans to any shareholders of the Company or repay existing indebtedness for borrowed money obligations. 
 Section 6.4 Conditions to Closing. The Company shall use best efforts to cause the conditions set forth in Article 8 to be satisfied with
respect to the Closing as soon as practicable. 
 Section 6.5 Reserve for Shares. The Company shall at all times reserve and keep
available such number of its duly authorized but unissued shares of Common Stock as is necessary to comply with the terms of this Agreement and the Convertible Notes and Conversion Shares. The Company shall at all times reserve and keep available
out of its duly authorized but unissued shares of Common Stock such number of its duly authorized shares of Common Stock as is necessary to comply with the terms of this Agreement, the Articles of Incorporation, as amended, and the Conversion
Shares. If at any time the number of shares of authorized but unissued Common Stock are not sufficient to comply with the terms of this Agreement, the Convertible Notes, and the Conversion Shares, the Company will promptly take such corporate action
as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares of Common Stock as are sufficient for such purpose. The Company will obtain any authorization, consent, approval or other action by or make
any filing with any court or administrative body that may be required under applicable securities laws in connection with the issuance of any shares issued by it in order to comply with the terms of this Agreement, the Convertible Notes, and the
Conversion Shares. 
 Section 6.6 Compliance with Law. The Company will conduct its business in compliance with all applicable
laws, rules and regulations of the jurisdictions in which it is conducting business, including, without limitation, all applicable local, state and federal environmental laws and regulations, the failure to comply with which would have a Material
Adverse Effect. 
 Section 6.7 Board of Directors Meetings. The Company shall use its best efforts to ensure that meetings of its
Board of Directors are held at least four (4) times each year and at least once each quarter. 
 Section 6.8 Use of
Proceeds. The Company shall use the cash proceeds of the Purchased Securities for the Company’s working capital needs and shall not use such proceeds for the satisfaction of any portion of the Company’s debt (other than payment of
trade payables in the ordinary course of the Company’s business and prior practices), or to redeem any Common Stock or Common Stock Equivalents or to settle any outstanding litigation. 
  

 26 

 Section 6.9 Certain Actions Requiring Investor Approval. The Company shall not, without a
vote or the written consent of the Investor: 
 (a) other than in the ordinary course of business, issue any debt securities
that are senior or pari passu in right of payment to or with the Convertible Notes; 
 (b) apply any of the
Company’s assets to the redemption, retirement, purchase or acquisition of, or dividends on, any shares of any class of equity or preferred security of the Company; or 
 (c) issue any equity securities of any subsidiary of the Company. 
 Section 6.10 Subsidiaries. The Company will not, nor will permit any Affiliate to, form or acquire any person which would thereby become a
subsidiary except to the extent such person is or, in the case of a formed person, will be, engaged in the businesses engaged in by the Company and immediately after such formation or acquisition (i) the equity interests of the acquired or
formed person are pledged to the Investor, and (ii) such person enters into documents requested by the Investor to provide that such person shall be obligated to repay the Notes and other amounts payable under the Transaction Documents, and to
grant to the Investor a first priority security interest (and to perfect such interest) subject to no other Liens, in the assets of such person. 
 Section 6.11 Participation in Future Financings. 
 (a) From the date hereof until the date that the
Notes are no longer outstanding, and subject to the rights granted to the purchasers pursuant to Section 4.13 of that certain Securities Purchase Agreement, dated as of March 5, 2004 (the “Midsummer Purchase Agreement”),
the Company will not, directly or indirectly, offer, sell, grant any option to purchase, or otherwise dispose of (or announce any offer, sale, grant or any option to purchase or other disposition of) any of its or its Subsidiaries’ Common Stock
or Common Stock Equivalents, including without limitation any debt, preferred stock or other instrument or security that is, at any time during its life and under any circumstances, convertible into or exchangeable or exercisable for Common Stock or
Common Stock Equivalents (any such offer, sale, grant, disposition or announcement being referred to as a “Subsequent Placement”). 
 (b) From the date hereof until the date that the Notes are no longer outstanding, the Company will not, directly or indirectly, effect any Subsequent Placement, unless the Company shall have first complied with
Section 4.13 of the Midsummer Purchase Agreement and the requirements of this Section 6.11(b): 
 (i) The Company
shall deliver to each Investor a written notice (the “Offer”) of any proposed or intended issuance or sale or exchange of the securities being offered (the “Offered Securities”) in a Subsequent Placement, which
Offer shall (w) identify and describe the Offered Securities, (x) describe the price and other terms upon which they are to be issued, sold or exchanged, and the number or amount of the Offered Securities to be issued, sold or 

  

 27 

 
exchanged, (y) identify the Persons or entities to which or with which the Offered Securities are to be offered, issued, sold or exchanged and
(z) offer to issue and sell to or exchange with each Investor the full amount of such Offered Securities upon the same price and other terms and conditions upon which they are to be issued, sold or exchanged. 
 (ii) To accept an Offer, the Investor must deliver a written notice to the Company prior to the end of the five (5) Business Day
period of the Offer, setting forth the Investor’s election to purchase the Offered Securities (the “Notice of Acceptance”). If the Investor does not deliver such a written notice by the end of such five (5) Business Day
period, then Investor shall be deemed to have rejected the Offer. 
 (iii) The Company shall have at least ten
(10) Business Days from the expiration of the period set forth in Section 6.11(b)(ii) above to issue, sell or exchange all or any part of such Offered Securities as to which a Notice of Acceptance has not been given by the Investor (the
“Refused Securities”), but only to the offerees described in the Offer and only upon terms and conditions (including, without limitation, number and price of shares, unit prices and interest rates, as applicable), taken as a whole,
that are not more favorable to the acquiring Person or Persons or less favorable to the Company than those set forth in the Offer. 
 (iv) Upon the closing of the issuance, sale or exchange of the Offered Securities, the Investor shall acquire from the Company, and the Company shall issue to the Investor, the number or amount of Offered Securities specified in the Notice
of Acceptance upon the terms and conditions specified in the Offer. The purchase by the Investor of any Offered Securities is subject in all cases to the preparation, execution and delivery by the Company and the Investor of a purchase agreement
relating to such Offered Securities reasonably satisfactory in form and substance to the Investor, the Company and their respective counsel. Notwithstanding anything to the contrary contained in this Agreement, if the Company does not consummate the
closing of the issuance, sale or exchange of the Refused Securities within ten (10) Business Days of the expiration of the period set forth in Section 6.11(b)(ii) or if the terms of the Offer or the amount of the Offered Securities shall
change prior to such closing, the Company shall provide the Investor with a second Offer setting forth the new terms of the Offered Securities, and the Investor shall have the same rights of participation with respect to such revised Offer as set
forth in this Section 6.11(b). 
 (v) The Company and the Investor agree that if the Investor elects to participate in
the Offer, (x) neither the agreement regarding the Subsequent Placement (the “Subsequent Placement Agreement”) with respect to such Offer nor any other transaction documents related thereto (collectively, the
“Subsequent Placement Documents”) shall include any term or provision whereby the Investor shall be required to agree to any restrictions in trading as to any securities of the Company owned by the Investor prior to such Subsequent
Placement, and (y) any 

  

 28 

 
registration rights set forth in such Subsequent Placement Documents shall be similar in all material respects to the registration rights contained in the
Registration Rights Agreement entered into in connection herewith. 
 (vi) Notwithstanding anything to the contrary in this
Section 6.11 and unless otherwise agreed to by Investor, the Company shall either confirm in writing to the Investor that the transaction with respect to the Subsequent Placement has been abandoned or shall publicly disclose its intention to
issue the Offered Securities, in either case in such a manner such that the Investor will not be in possession of material non-public information, by the 19th Business Day following delivery of the Offer. If by the 19th Business Day following
delivery of the Offer no public disclosure regarding a transaction with respect to the Offered Securities has been made, and no notice regarding the abandonment of such transaction has been received by the Investor, such transaction shall be deemed
to have been abandoned and the Investor shall not be deemed to be in possession of any material, non-public information with respect to the Company. Should the Company decide to pursue such transaction with respect to the Offered Securities, the
Company shall provide the Investor with another Offer and the Investor will again have the right of participation set forth in this Section 6.11. The Company shall not be permitted to deliver more than one such Offer to the Investor in any
sixty (60) day period. 
 (vii) Any Offered Securities not acquired by the Investor or other Persons in accordance with
this Section 6.11(b) above may not be issued, sold or exchanged until they are again offered to the Investor under the procedures specified in this Agreement. 
 (c) Notwithstanding anything in this Agreement to the contrary, the restrictions contained in paragraph (b) of this Section 6.11
shall not apply to the issuance of Common Stock (A) pursuant to any Exempt Issuance (provided that such exercise or conversion occurs in accordance with the terms thereof, without amendment or modification, and that the applicable exercise or
conversion price or ratio is described in such schedule) or otherwise pursuant to any employee benefit plan described in Section 4.38 above or hereafter adopted by the Company and approved by its shareholders, (B) pursuant to a bona fide
firm commitment underwritten public offering with a nationally recognized underwriter (excluding any equity lines) in an aggregate offering amount greater than $15,000,000, or (C) in connection with a bona fide joint venture, acquisition,
merger, strategic partnership, or strategic alliance the primary purpose of which is not to raise cash. 
 Section 6.12 Dividends;
Subsequent Equity Sales. 
 (a) From the date hereof until 90 days after the Effective Date, other than as contemplated by
this Agreement, neither the Company nor any Affiliate shall issue or sell shares of Common Stock or Common Stock Equivalents entitling any person to acquire shares of Common Stock; provided, however, the 90 day period set forth in this
Section 4.14 shall be extended for the number of Trading Days during such period in which 

  

 29 

 
(i) trading in the Common Stock is suspended by any Trading Market, or (ii) following the Effective Date, the Registration Statement is not
effective or the prospectus included in the Registration Statement may not be used by the Investor for the resale of the Underlying Shares. 
 (b) From the date hereof until such time as the Investor no longer holds any of the Notes, or Conversion Shares, the Company shall be prohibited from effecting or entering into an agreement to effect any Subsequent
Financing involving a Variable Rate Transaction. “Variable Rate Transaction” means a transaction in which the Company issues or sells (i) any debt or equity securities that are convertible into, exchangeable or exercisable for,
or include the right to receive additional shares of Common Stock either (A) at a conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at
any time after the initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon
the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into any agreement, including, but not limited to, an equity line of credit,
whereby the Company may sell securities at a future determined price. 
 (c) Unless Shareholder Approval has been obtained and
deemed effective, neither the Company nor any Affiliate shall make any issuance whatsoever of Common Stock or Common Stock Equivalents which would cause any adjustment of the Conversion Price to the extent the holder(s) of the Notes and Conversion
Shares would not be permitted to convert the outstanding Notes in full, ignoring for such purposes the conversion or exercise limitations therein. The Investor shall be entitled to obtain injunctive relief against the Company to preclude any such
issuance, which remedy shall be in addition to any right to collect damages. In addition, prior to the receipt of Shareholder Approval, the Company shall not pay any cash dividend on its Common Stock while any of the Notes remain outstanding.

 (d) Notwithstanding the foregoing, this Section 6.12 shall not apply with respect to an Exempt Issuance, except that
no Variable Rate Transaction shall be an Exempt Issuance. 
  

 30 

 Section 6.13 Transfer Restrictions. 
 (a) The Conversion Shares may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of
Conversion Shares other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Investor or in connection with a pledge as contemplated in Section 6.13(b), the Company may require the transferor
thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer
does not require registration of such transferred Conversion Shares under the Securities Act. As a condition of transfer of Conversion Shares other than pursuant to an effective registration statement or Rule 144, any such transferee shall agree in
writing to be bound by the terms of this Agreement and shall have the rights of an Investor under this Agreement and the Registration Rights Agreement. 
 (b) The Investor agrees to the imprinting, so long as is required by this Section 6.13, of a legend on any of the Conversion Shares in the following form: 
 [NEITHER] THIS SECURITY [NOR THE SECURITIES INTO WHICH THIS SECURITY IS [EXERCISABLE] [CONVERTIBLE]] HAS [NOT] BEEN REGISTERED WITH THE SECURITIES AND
EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT
TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES
LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY [AND THE SECURITIES ISSUABLE UPON [EXERCISE] [CONVERSION] OF THIS SECURITY] MAY BE
PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES. 
 The Company acknowledges and agrees that
the Investor may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant a security interest in some or all of the Conversion Shares to a financial institution that is an “accredited
investor” as defined in Rule 501(a) under the Securities Act and who agrees to be bound by the provisions of this Agreement and the Registration Rights Agreement and, if required under the terms of such arrangement, the Investor may transfer
pledged or secured Conversion Shares to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company, and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in
connection therewith. Further, no notice shall be required of such pledge. At the Investor’s expense, the Company will execute and deliver such reasonable documentation as a pledgee or 

  

 31 

 
secured party of Conversion Shares may reasonably request in connection with a pledge or transfer of the Conversion Shares , including, if the Conversion
Shares are subject to registration pursuant to the Registration Rights Agreement, the preparation and filing of any required prospectus supplement under Rule 424(b)(3) under the Securities Act or other applicable provision of the Securities Act to
appropriately amend the list of Selling Shareholders thereunder. 
 (c) Certificates evidencing the Conversion Shares shall
not contain any legend (including the legend set forth in Section 6.13(b) hereof): (i) while a registration statement (including the Registration Statement) covering the resale of such security is effective under the Securities Act, or
(ii) following any sale of such Conversion Shares pursuant to Rule 144, or (iii) if such Underlying Shares are eligible for sale under Rule 144(k), or (iv) if such legend is not required under applicable requirements of the
Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission). The Company shall cause its counsel to issue a legal opinion to its transfer agent promptly after the Effective Date if required by the
transfer agent to effect the removal of the legend hereunder. If all or any portion of a Note is converted or exercised (as applicable) at a time when there is an effective registration statement to cover the resale of the Conversion Shares, or if
such Conversion Shares may be sold under Rule 144(k) or if such legend is not otherwise required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission) then
such Conversion Shares shall be issued free of all legends. The Company agrees that following the Effective Date or at such time as such legend is no longer required under this Section 6.13(c), it will, no later than seven Trading Days
following the delivery by the Investor to the Company or the Transfer Agent of a certificate representing Conversion Shares, as applicable, issued with a restrictive legend (such third Trading Day, the “Legend Removal Date”),
deliver or cause to be delivered to the Investor a certificate representing such shares that is free from all restrictive and other legends. The Company may not make any notation on its records or give instructions to the transfer agent that enlarge
the restrictions on transfer set forth in this Section. Certificates for Conversion Shares subject to legend removal hereunder shall be transmitted by the transfer agent to the Investor by crediting the account of the Investor’s prime broker
with the Depository Trust Company System. 
 (d) In addition to the Investor’s other available remedies, the Company
shall pay to the Investor, in cash, as liquidated damages and not as a penalty, for each $1,000 of Conversion Shares (based on the VWAP of the Common Stock on the date such Conversion Shares are submitted to the transfer agent) delivered for removal
of the restrictive legend and subject to Section 6.13(c), $10 per Trading Day (increasing to $20 per Trading Day 5 Trading Days after such damages have begun to accrue) for each Trading Day after the second Trading Day following the Legend
Removal Date until such certificate is delivered without a legend. Nothing herein shall limit the Investor’s right to pursue actual damages for the Company’s failure to deliver certificates representing any Conversion Shares as required by
the Transaction Documents, and the Investor shall have the right to pursue all remedies available to it at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief. 
  

 32 

 (e) The Investor agrees that the removal of the restrictive legend from certificates
representing Conversion Shares as set forth in this Section 6.13 is predicated upon the Company’s reliance that the Investor will sell any Conversion Shares pursuant to either the registration requirements of the Securities Act, including
any applicable prospectus delivery requirements, or an exemption therefrom, and that if Conversion Shares are sold pursuant to a Registration Statement, they will be sold in compliance with the plan of distribution set forth therein. 
 Section 6.14 Securities Law Disclosure; Publicity. The Company shall, by 12:00 p.m. (New York City time) on the fourth Trading Day following
the date hereof (or such shorter time period as shall be required by Form 8-K or otherwise agreed to by the parties), issue a Current Report on Form 8-K disclosing the material terms of the transactions contemplated hereby and attaching the
Transaction Documents as exhibits thereto. The Company and the Investor shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor the Investor shall issue any
such press release or otherwise make any such public statement without the prior consent of the Company, with respect to any press release of the Investor, or without the prior consent of the Investor, with respect to any press release of the
Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or
communication. Notwithstanding the foregoing, the Company shall not include the name of the Investor in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of the Investor, except (i) as
required by federal securities law in connection with (A) any registration statement contemplated by the Registration Rights Agreement and (B) the filing of final Transaction Documents (including signature pages thereto) with the
Commission and (ii) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Investor with prior notice of such disclosure permitted under this clause (ii). 
 Section 6.15 Form D; Blue Sky Filings. The Company agrees to timely file a Form D with respect to the offering described herein as required
under Regulation D and to provide a copy thereof, promptly upon request of the Investor. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Notes and
Conversion Shares for, sale to the Investor at the Closing under applicable securities or “Blue Sky” laws of the states of the United States, and shall provide evidence of such actions promptly upon request of the Investor. 
 Section 6.16 Shareholder Approval. The Company shall use its best efforts to obtain Shareholder Approval at the Company’s 2007 Annual
Meeting of Shareholders, which shall be held no later than September 30, 2007 (such date, the “Required Shareholder Approval Date”). The proxy for such Annual Meeting shall contain the recommendation of the Company’s Board
of Directors that such proposal be approved. The Company shall solicit proxies from its shareholders in connection therewith in the same manner as all other management proposals in such proxy statement and all management-appointed proxyholders shall
vote their proxies in favor of such proposal. 
  

 33 

 Section 6.17 Reservation and Listing of Shares. 
 (a) The Company shall maintain a reserve from its duly authorized shares of Common Stock for issuance pursuant to the Transaction
Documents in such amount as may be required to fulfill its obligations in full under the Transaction Documents. 
 (b) The
Company shall, if applicable: (i) in the time and manner required by the principal Trading Market, prepare and file with such Trading Market an additional shares listing application covering a number of shares of Common Stock at least equal to
the Required Minimum on the date of such application, (ii) take all steps necessary to cause such shares of Common Stock to be approved for listing on such Trading Market as soon as possible thereafter, (iii) provide to the Investor
evidence of such listing, and (iv) maintain the listing of such Common Stock on any date at least equal to the Required Minimum on such date on such Trading Market or another Trading Market; provided that such listing shall include any
additional shares that may be issuable under the Note as a result of any adjustments to the Conversion Price that would affect the number of Conversion Shares issuable to the Investor. 
 Section 6.18 Limitation on Indebtedness. So long as any Purchased Securities remain outstanding, the Company’s obligations under the
Bank of America Credit Agreement or any other bank, credit or other lending facility with any other lender shall not exceed the greater of (i) $5,000,000 or (ii) 60% of the Company’s accounts receivable balance (as reflected on the
Company’s financial statements contained in its most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K, as applicable). Any failure to satisfy the foregoing test shall result in an event of default under the Note. 

Section 6.19 Mortgage on Real Property. So long as the Investor (or one of its Affiliates) continues to hold at least 50% of the original
principal amount of the Notes, the Company hereby certifies that it will not grant a first mortgage (the “Mortgage”) on the Company’s property located at 6950 Bryan Dairy Road, Largo, Florida 33777, or any subsequent location
that may become the Company’s headquarters (the “Real Property”). The Company and Investor hereby agree that, after the Closing and during any such time as at least 50% of the original principal amount of the Notes shall remain
outstanding, the Company shall, if requested in writing by Investor, provide to Investor a Mortgage on the Real Property on commercially reasonable terms to further secure the Company’s obligations to the Investor under the Notes;
provided, however, that Investor shall be solely responsible for all costs and expenses of obtaining such a Mortgage, including without limitation all appraisal fees, recording fees and documentary stamp taxes, relating to the
preparation, execution and filing of the Mortgage on the Real Property. Investor shall reimburse, indemnify and hold the Company harmless from all such costs and expenses. 
 ARTICLE VII 
 CONDITIONS TO OBLIGATION OF THE COMPANY 
 The obligation of the Company to sell Purchased Securities to the Investor at the Closing is subject to the satisfaction, on or before the Closing, of
the conditions set forth in this Article 7. 
  

 34 

 Section 7.1 Representations and Warranties. The representations and warranties contained in
Article 5 shall be true, complete and correct as of the date hereof and, as of the Closing Date as though such representations and warranties had been made on and as of such date. 
 Section 7.2 Performance. The Investor shall have performed and complied in all material respects with all agreements contained herein, and in
the agreements, documents and instruments contemplated hereby which are required to be performed or complied with by them prior to or at the date of the Closing. 
 Section 7.3 Required Consents. The Company shall have obtained the written consent or approval of each person whose consent or approval is required in connection with this Agreement. 
 Section 7.4 Litigation. No suit, action or other proceeding shall be pending or, to the knowledge of Company, threatened by any third party
or by or before any court or governmental agency in which it is sought to restrain or prohibit or to obtain damages or other relief in connection with this Agreement or the consummation of the transactions contemplated hereby, and no investigation
that might result in any such suit, action or other proceeding shall be pending or, to the knowledge of the Company, threatened. 
 Section 7.5 Legislation. No statute, rule, regulation, order, or interpretation shall have been enacted, entered or deemed applicable by any domestic or foreign government or governmental or administrative agency or court which
would make the transactions contemplated by this Agreement illegal. 
 ARTICLE VIII 
 CONDITIONS TO THE OBLIGATIONS OF INVESTOR 
 The obligation of the Investor to purchase the Purchased Securities at the Closing is subject to the satisfaction, on or before the Closing, of the conditions set forth in this Article 7. 
 Section 8.1 Representations and Warranties. The representations and warranties contained in Article 4 shall be true, complete and correct as
of the date hereof and, as of the Closing Date (as though such representations and warranties had been made on and as of such date), and the Chief Executive Officer and Chief Financial Officer of the Company shall have certified to such effect to
the Investor in writing. 
 Section 8.2 Performance. The Company shall have performed and complied in all material respects with
all agreements contained herein, and in the agreements, documents and instruments contemplated hereby which are required to be performed or complied with by it prior to or at the date of the Closing, and the Chief Executive Officer and Chief
Financial Officer of the Company shall have certified to the Investor in writing to such effect and to the further effect that all of the conditions set forth in this Article 8 have been satisfied. 
 Section 8.3 All Proceedings to be Satisfactory. All corporate and other proceedings to be taken by the Company in connection with the
transactions contemplated hereby and all documents incident thereto shall be reasonably satisfactory in form and substance to the Investor and their counsel, and the Investor and their counsel shall have received all such counterpart originals or
certified or other copies of such documents as they reasonably may request. 
  

 35 

 Section 8.4 Shareholder Approval. Any required Shareholder Approval shall have been obtained
by the Company. 
 Section 8.5 Supporting Documents. 
 (a) The Company shall have delivered to the Investor an opinion of counsel in form and content reasonably satisfactory to the Investor.

 (b) The Investor and their counsel shall have received copies of the following documents: 
 (i) a certificate of the Secretary of State of the state of incorporation of the Company and each of its Affiliates dated as of a date
within three days prior to the Closing Date as to the corporate existence of the Company and each of its Affiliates and listing all documents of the Company and each of its Affiliates on file with such Secretary of State; 
 (ii) a certificate of the Secretary of the Company dated the Closing Date and certifying: (A) the Company’s and each
Affiliate’s then current Articles of Incorporation and Bylaws; (B) that attached thereto is a true and complete copy of all resolutions adopted by the Board of Directors of the Company authorizing the execution, delivery and performance of
this Agreement and the Transaction Documents, and the issuance, sale and delivery of the Purchased Securities and the Conversion Shares, and that all such resolutions are in full force and effect and are all the resolutions adopted in connection
with the transactions contemplated by this Agreement and the Transaction Documents; and (C) to the incumbency and specimen signature of each officer of the Company and its Affiliates executing this Agreement, the Transaction Documents, and any
certificate or instrument furnished pursuant hereto, and a certification by another officer of the Company as to the incumbency and signature of the officer signing the certificate referred to in this subsection (ii); and 
 (iii) such additional supporting documents and other information with respect to the operations and affairs of the Company as any Investor
or the Investor’s counsel reasonably may request. 
 Section 8.6 Required Consents. The Company shall have obtained the
written consent or approval, in form and substance reasonably satisfactory to the Investor, of each person whose consent or approval is required in connection with this Agreement. 
 Section 8.7 Litigation. No suit, action or other proceeding shall be pending or, to the knowledge of the Company, threatened by any third
party or by or before any court or governmental agency in which it is sought to restrain or prohibit or to obtain damages or other relief in connection with this Agreement or the consummation of the transactions contemplated hereby, and no
investigation that might result in any such suit, action or other proceeding shall be pending or, to the knowledge of Company, threatened. 
  

 36 

 Section 8.8 Legislation. No statute, rule, regulation, order, or interpretation shall have
been enacted, entered or deemed applicable by any domestic or foreign government or governmental or administrative agency or court which would make the transactions contemplated by this Agreement illegal. 
 Section 8.9 No Material Adverse Changes. Since the date of this Agreement, no events shall have occurred or circumstances arisen which are
reasonably expected, individually or in the aggregate, to have or result in a Material Adverse Effect upon the Company. The Company shall fully cooperate as reasonably requested by the Investor to enable the Investor to determine that this condition
has been satisfied. 
 Section 8.10 Liens. There shall exist as of the Closing no Liens, other than Permitted Liens, on any
assets or properties of the Company. 
 Section 8.11 Transaction Documents. 
 (a) The Company and the Investor shall have executed and delivered each of the Transaction Documents to which it is a party. Each such
document or agreement shall constitute the valid and binding obligation of such party, enforceable against such party in accordance with its terms. 
 (b) The Company, the Investor and Bank of America (as the lender under the Bank of America Loan Agreement) shall have executed and delivered an Intercreditor Agreement, and such Intercreditor Agreement shall
constitute the valid and binding obligation of the parties thereto enforceable in accordance with its terms. 
 Section 8.12 Prior
Preemptive Rights. All of the Company’s obligations regarding pre emptive or first refusal rights with respect to the issuance of its securities shall have been terminated in their entirety or duly waived pursuant to a written instrument in
form and content satisfactory to the Investor and the Investor’s counsel with respect to (a) the issuance of the Purchased Securities and (b) the issuance of the Conversion Shares. 
 Section 8.13 No Default. Since the date hereof, no default (or event which, with the passage of time and/or the giving of notice, would
constitute a default) of the Company shall have occurred under this Agreement or any of the Transaction Documents. 
 Section 8.14
Payment of Fees. The Company shall have paid the fees and expenses of the Investor’s legal counsel as required under Section 11.7. 
 ARTICLE IX 
 INDEMNIFICATION 
 Section 9.1 Indemnification of Investor. The Company shall indemnify, defend and hold harmless the Investor and their respective subsidiaries, officers, directors and stockholders from and against and in
respect of any and all demands, claims, actions or causes of action, 

  

 37 

 
assessments, losses, damages, liabilities, interest and penalties, costs and expenses (including, without limitation, reasonable legal fees and disbursements
incurred in connection therewith and in seeking indemnification therefor, and any amounts or expenses required to be paid or incurred in connection with any action, suit, proceeding, claim, appeal, demand, assessment or judgment)
(“Indemnifiable Losses”), resulting from, arising out of, or imposed upon or incurred by any person to be indemnified hereunder by reason of any breach of any representation, warranty, covenant or agreement of the Company contained
in this Agreement or any agreement, certificate contemplated by this Agreement or any agreement, certificate, or document executed and delivered by the Company pursuant hereto or in connection with any of the transactions contemplated by this
Agreement. 
 Section 9.2 Indemnification of the Company. The Investor shall indemnify, defend and hold harmless the Company and
each of its subsidiaries, officers, directors and stockholders from and against and in respect of any and all Indemnifiable Losses resulting from, arising out of, or imposed upon or incurred by any person to be indemnified hereunder by reason of any
breach of any representation, warranty, covenant or agreement by the Investor contained in this Agreement or any agreement, certificate or document executed and delivered by the Investor pursuant hereto or in connection with any of the transactions
contemplated by this Agreement. 
 Section 9.3 Third-Party Claims. If a claim by a third party is made against an indemnified
party and if the indemnified party intends to seek indemnity with respect thereto under this Article 9, such indemnified party shall promptly notify the indemnifying party of such claim; provided, however, that failure to give timely
notice shall not affect the rights of the indemnified party so long as the failure to give timely notice does not adversely affect the indemnifying party’s ability to defend such claim against a third party. The indemnified party shall not
settle such claim without the consent of the indemnifying party, which consent shall not be unreasonably withheld or delayed. If the indemnifying party acknowledges in writing its indemnity obligations for Indemnifiable Losses resulting therefrom,
the indemnifying party may participate at its own cost and expense in the settlement or defense of any claim for which indemnification is sought. 
 Section 9.4 Cooperation as to Indemnified Liability. Each party hereto shall cooperate fully with the other parties with respect to access to books, records, or other documentation within such party’s control, if deemed
reasonably necessary or appropriate by any party in the defense of any claim which may give rise to indemnification hereunder. 
 ARTICLE X

 TERMINATION AND DEFAULT 
 Section 10.1 Termination. The obligation of the parties hereto to consummate the remaining transactions contemplated hereby may be terminated and abandoned at any time at or before the Closing if any of the following events
occurs: 
 (a) by and at the written option of the Investor or the Company if the Closing shall not have occurred on or before
April 16, 2007, provided that the terminating party shall not have breached in any material respect its obligations under this Agreement in any manner that shall have been the proximate cause of or resulted in, the failure to complete
the Closing by such date; or 
  

 38 

 (b) by Investor if there shall have occurred any event that would constitute a Material
Adverse Effect for the Company; or 
 (c) by the mutual written consent of each of the parties; or 
 (d) by and at the option of the Investor or the Company if any governmental authority shall have issued an order, decree, or ruling or
taken any other action restraining, enjoining or otherwise prohibiting in any material respects the transactions contemplated hereby and such order, decree, ruling or other action shall have become final and nonappealable. 
 Section 10.2 Effect. 
 (a) Upon termination of this Agreement, the Investor’s rights and obligations to purchase any Convertible Notes or Conversion Shares pursuant to Article 2 hereof shall terminate. 
 (b) Termination of this Agreement by a party shall not relieve any other party hereto of any liability for breach of representation,
warranty, covenant or agreement by such other parties including liability for monetary damages and/or specific performance. 
 ARTICLE XI

 OTHER PROVISIONS 
 Section 11.1 Further Assurances. At such time and from time to time on and after the date hereof upon request by the Investor, the Company will execute, acknowledge and deliver, or will cause to be done, executed, acknowledged
and delivered, all such further acts, certificates and assurances that may be reasonably required for the better conveying, transferring, assigning, delivering, assuring and confirming to the Investor, or to the Investor’s respective successors
and assigns, all of the Conversion Shares or to otherwise carry out the purposes of this Agreement and the agreements, documents and instruments contemplated hereby. 
 Section 11.2 Complete Agreement. The Schedules and Exhibits to this Agreement shall be construed as an integral part of this Agreement to the same extent as if they had been set forth verbatim herein. This
Agreement and the Schedules and Exhibits hereto constitute the entire agreement between the parties hereto with respect to the subject matters hereof and thereof and supersede all prior agreements whether written or oral relating hereto. 

Section 11.3 Survival of Representations, Warranties and Agreements. The representations, warranties, covenants and agreements contained
herein shall survive the Closing and remain in full force and effect; provided, however, that the representations and warranties shall expire on the second anniversary of the date of the Closing hereunder. No independent investigation
of the Company by the Investor, its counsel, or any of its agents or employees shall in any way limit or restrict the scope of the representations and warranties made by the Company in this Agreement. 
  

 39 

 Section 11.4 Consent, Waiver, Amendment, Etc. The failure of any party hereto to enforce at
any time any of the provisions of this Agreement shall not, absent an express written waiver signed by the party making such waiver specifying the provision being waived, be construed to be a waiver of any such provision, nor in any way to affect
the validity of this Agreement or any part thereof or the right of the party thereafter to enforce each and every such provision. No waiver of any breach of this Agreement shall be held to be a waiver of any other or subsequent breach. Except as
otherwise specifically provided herein, in each case in which approval of the Investor is required by the terms of this Agreement, such requirement shall be satisfied by a vote or the written consent of the Investor. With the written consent of the
Investor, the obligations of the Company under this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), and with the same approval the Company may amend or eliminate any of the provisions
of this Agreement; provided, however, that no such waiver or amendment shall, without the written consent of the holders of all Purchased Securities at the time outstanding, amend this Section 11.4. Written notice of any such
waiver, amendment, or consent shall be given to the record holders of the Purchased Securities who have not previously consented thereto in writing. Neither this Agreement nor any provision hereof may be changed, waived, discharged or terminated
orally, but only by a statement in writing signed by the party against which enforcement of the change, waiver, discharge or termination is sought, except to the extent provided in this Section 11.4. 
 Section 11.5 Notices. All notices or other communications to a party required or permitted hereunder shall be in writing and shall be
delivered personally or by facsimile (receipt confirmed electronically) to such party (or, in the case of any entity, to an executive officer of such party) or shall be sent by a reputable express delivery service or by certified mail, postage
prepaid with return receipt requested, addressed as follows: 
 if to the Investor to: 
 Whitebox Pharmaceutics Growth Fund, LLC 
 Suite 300 
 3033 Excelsior Boulevard 
 Minneapolis, MN 55416 
 Attn: Dale Willenbring 
 with a copy to: 
 Theodore C. Cadwell, Jr., Esq. 
 Dorsey & Whitney LLP 
 50 S.
6th Street 
 Suite 1500 
 Minneapolis, Minnesota 55402 
  

 40 

 if to the Company to: 
 GeoPharma, Inc. 
 6950 Bryan Dairy Road 
 Largo, Florida 33777 
 Attn: Jay Taneja 
 with a copy
to: 
 Julio C. Esquivel, Esq. 
 Shumaker, Loop & Kendrick, LLP 
 101 East Kennedy Boulevard 
 Suite 2800 
 Tampa, FL 33602-5151 
 Any party may change the above-specified recipient and/or mailing address by notice to all other parties given in the manner
herein prescribed. All notices shall be deemed given on the day when actually delivered as provided above (if delivered personally or by facsimile) or on the day shown on the return receipt (if delivered by mail or delivery service). 
 Section 11.6 Public Announcement. In the event any party proposes to issue any press release or public announcement concerning any provisions
of this Agreement or the transactions contemplated hereby, such party shall so advise the other parties hereto, and the parties shall thereafter use their reasonable best efforts to cause a mutually agreeable release or announcement to be issued. No
party will publicly disclose or divulge any provisions of this Agreement or the transactions contemplated hereby without the other parties’ written consent, except as may be required by applicable law (including applicable rules and regulations
of the SEC) or stock exchange regulation, and except for communications to employees. 
 Section 11.7 Expenses. Subject to the
following sentence, the Company and the Investor shall each pay their own expenses incident to this Agreement and the preparation for, and consummation of, the transactions provided for herein. Whether or not a Closing occurs, the Company shall
reimburse the Investor for one-half of its legal fees and expenses incurred in connection with the drafting, negotiation, due diligence and execution of this Agreement and the Transaction Documents and the consummation of the transactions
contemplated herein and therein. The Company shall also reimburse the Investor for all legal fees and expenses incurred in connection with the drafting, negotiation and execution of any waivers or amendments to this Agreement or any Transaction
Document. 
 Section 11.8 Governing Law. All questions concerning the construction, validity, enforcement and interpretation of
this Agreement and the other Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of Minnesota, without regard to the principles of conflicts of law thereof. Each party agrees that
all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors,
officers, shareholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the State of Minnesota. 

  

 41 

 
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the State of Minnesota for the adjudication of
any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert
in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. If either party shall commence an
action or proceeding to enforce any provisions of the Transaction Documents, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred
with the investigation, preparation and prosecution of such action or proceeding. 
 Section 11.9 Titles and Headings;
Construction. The titles and headings to the Articles and Sections herein are inserted for the convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. This Agreement shall
be construed without regard to any presumption or other rule requiring construction hereof against the party causing this Agreement to be drafted. 
 Section 11.10 Benefit. Nothing in this Agreement, expressed or implied, is intended to confer on any person other than the parties hereto or their respective successors or assigns, any rights, remedies, obligations or
liabilities under or by reason of this Agreement. 
 Section 11.11 Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be deemed as original and all of which together shall constitute one instrument. 
 Section 11.12
Parties in Interest. All representations, covenants and agreements contained in this Agreement by or on behalf of any of the parties hereto shall bind and inure to the benefit of and be enforceable by the respective successors and assigns of
the parties hereto, whether so expressed or not, and, in particular, shall inure to the benefit of and be enforceable by the holder or holders at the time of any of the Purchased Securities. 
 Section 11.13 Severability. If any provision of this Agreement is held invalid by a court of competent jurisdiction, the remaining provisions
shall nonetheless be enforceable according to their terms. Further, if any provision is held to be overbroad as written, such provision shall be deemed amended to narrow its application to the extent necessary to make the provision enforceable
according to applicable law and shall be enforced as amended. 
 [SIGNATURE PAGES FOLLOW] 
  

 42 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement to be effective as of the date
first written above. 
  

			
	GEOPHARMA, INC.
	a Florida corporation
		
	By:	 	  

	Name:	 	
	Title:	 	

  

 43 

 IN WITNESS WHEREOF, the undersigned has executed this Agreement to be effective as of the date
first written above. 
  

			
	INVESTOR:
	
	 WHITEBOX PHARMACEUTICAL GROWTH
 FUND, LTD.

		
	By:	 	  

	Name:	 	
	Title:	 	

  

			
	Address:	  	Suite 300
		  	3033 Excelsior Boulevard
		  	Minneapolis, MN 55415

  

 44 

 EXHIBIT A 
 FORM OF CONVERTIBLE PROMISSORY NOTE 
 (attached hereto) 
  

 A-1 

 EXHIBIT B 
 FORM OF SECURITY AGREEMENT 
 (attached hereto) 
  

 B-1 

 EXHIBIT C 
 FORM OF REGISTRATION RIGHTS AGREEMENT 
 (attached hereto) 
  

 C-1 

 EXHIBIT D 
 FORM OF PLEDGE AGREEMENT 
 (attached hereto) 
  

 D-1 

 EXHIBIT E 
 FORM OF GUARANTY 
 (attached hereto) 
  

 E-1 

 EXHIBIT F 
 FORM OF INTERCREDITOR AGREEMENT 
 (attached hereto) 
  

 F-1 

 EXHIBIT G 
 FORM OF VOTING AGREEMENT 
 (attached hereto) 
  

 G-1 

 EXHIBIT H 
 GEOPHARMA SHAREHOLDERS EXECUTING VOTING AGREEMENTS 
  

			
	 Shareholder List
	  	 # of
 Shares

	 First Dehli Trust
	  	60,856
	 Jugal Taneja
	  	558,269
	 Jugal Taneja & Manju Taneja
	  	17,098
	 Manju Taneja
	  	369,817
	 Mihir Taneja
	  	501,025
	 Dynamic Health Products, Inc.
 Mandeep Taneja
	  	108,905
84,921
	 Carnegie Capital, Ltd.
	  	582,537
		  	 
	 Taneja Family Total
	  	2,283,428
		
	 Carol Dore-Falcone
	  	94,648
	 Kotha Sekharam
	  	236,610
	 Madhavi Sekharam
	  	23,223
		  	 
	 Others Total
	  	354,481
		
	 Grand Total (Taneja Family & Others)
	  	2,637,909

  

 H-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00121-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00121-of-00352.parquet"}]]